Literature DB >> 20038212

Differential transcriptional responses to interferon-alpha and interferon-gamma in primary human hepatocytes.

Xiao-Song He1, Santosh Nanda, Xuhuai Ji, Gloria M Calderon-Rodriguez, Harry B Greenberg, T Jake Liang.   

Abstract

Interferon (IFN) plays a central role in the innate and adaptive antiviral immune responses. While IFN-alpha is currently approved for treating chronic hepatitis B and hepatitis C, in limited studies, IFN-gamma has not been shown to be effective for chronic hepatitis B or C. To identify the potential mechanism underlying the differential antiviral effects of IFN-alpha and IFN-gamma, we used cDNA microarray to profile the global transcriptional response to IFN-alpha and IFN-gamma in primary human hepatocytes, the target cell population of hepatitis viruses. Our results reveal distinct patterns of gene expression induced by these 2 cytokines. Overall, IFN-alpha induces more genes than IFN-gamma at the transcriptional level. Distinct sets of genes were induced by IFN-alpha and IFN-gamma with limited overlaps. IFN-alpha induces gene transcription at an early time point (6 h) but not at a later time point (18 h), while the effects of IFN-gamma are more prominent at 18 h than at 6 h, suggesting a delayed transcriptional response to IFN-gamma in the hepatocytes. These findings indicate differential actions of IFN-alpha and IFN-gamma in the context of therapeutic intervention for chronic viral infections in the liver.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20038212      PMCID: PMC2947462          DOI: 10.1089/jir.2009.0082

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  40 in total

1.  Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics.

Authors:  Robert E Lanford; Bernadette Guerra; Helen Lee; Deborah Chavez; Kathleen M Brasky; Catherine B Bigger
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

2.  Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C.

Authors:  Ying Huang; Jordan J Feld; Ronda K Sapp; Santosh Nanda; Jiing-Huey Lin; Lawrence M Blatt; Michael W Fried; Krishna Murthy; T Jake Liang
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

3.  Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race.

Authors:  Xiao-Song He; Xuhuai Ji; Matthew B Hale; Ramsey Cheung; Aijaz Ahmed; Yaqian Guo; Garry P Nolan; Lawrence M Pfeffer; Teresa L Wright; Neil Risch; Robert Tibshirani; Harry B Greenberg
Journal:  Hepatology       Date:  2006-08       Impact factor: 17.425

4.  Differential gene induction by type I and type II interferons and their combination.

Authors:  Corneliu Sanda; Patrick Weitzel; Takuma Tsukahara; Joel Schaley; Howard J Edenberg; Matthew A Stephens; Jeanette N McClintick; Lawrence M Blatt; Lang Li; Leonid Brodsky; Milton W Taylor
Journal:  J Interferon Cytokine Res       Date:  2006-07       Impact factor: 2.607

5.  Production of infectious hepatitis C virus of various genotypes in cell cultures.

Authors:  Takanobu Kato; Takuya Matsumura; Theo Heller; Satoru Saito; Ronda K Sapp; Krishna Murthy; Takaji Wakita; T Jake Liang
Journal:  J Virol       Date:  2007-02-14       Impact factor: 5.103

6.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

Authors:  George K K Lau; Teerha Piratvisuth; Kang Xian Luo; Patrick Marcellin; Satawat Thongsawat; Graham Cooksley; Edward Gane; Michael W Fried; Wan Cheng Chow; Seung Woon Paik; Wen Yu Chang; Thomas Berg; Robert Flisiak; Philip McCloud; Nigel Pluck
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

7.  Replication of hepatitis C virus (HCV) RNA in mouse embryonic fibroblasts: protein kinase R (PKR)-dependent and PKR-independent mechanisms for controlling HCV RNA replication and mediating interferon activities.

Authors:  Kyung-Soo Chang; Zhaohui Cai; Chen Zhang; Ganes C Sen; Bryan R G Williams; Guangxiang Luo
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

8.  Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector.

Authors:  Karla J Helbig; Daryl T-Y Lau; Ljiljana Semendric; Hugh A J Harley; Michael R Beard
Journal:  Hepatology       Date:  2005-09       Impact factor: 17.425

9.  Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy.

Authors:  Marcello Persico; Mario Capasso; Eliana Persico; Monica Svelto; Roberta Russo; Daniela Spano; Lori Crocè; Vincenzo La Mura; Francesco Moschella; Flora Masutti; Roberto Torella; Claudio Tiribelli; Achille Iolascon
Journal:  Hepatology       Date:  2007-10       Impact factor: 17.425

Review 10.  Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B.

Authors:  Lawrence Lai; Chee-Kin Hui; Nancy Leung; George K Lau
Journal:  Int J Nanomedicine       Date:  2006
View more
  10 in total

1.  Identification of an intrahepatic transcriptional signature associated with self-limiting infection in the woodchuck model of hepatitis B.

Authors:  Simon P Fletcher; Daniel J Chin; Donavan T Cheng; Palanikumar Ravindran; Hans Bitter; Lore Gruenbaum; Paul J Cote; Han Ma; Klaus Klumpp; Stephan Menne
Journal:  Hepatology       Date:  2013-01       Impact factor: 17.425

2.  Inhibition of alpha interferon (IFN-α)-induced microRNA-122 negatively affects the anti-hepatitis B virus efficiency of IFN-α.

Authors:  Junli Hao; Wensong Jin; Xinghui Li; Saifeng Wang; Xiaojun Zhang; Hongxia Fan; Changfei Li; Lizhao Chen; Bin Gao; Guangze Liu; Songdong Meng
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

Review 3.  Organ system view of the hepatic innate immunity in HCV infection.

Authors:  Bo-Ram Bang; Sandra Elmasry; Takeshi Saito
Journal:  J Med Virol       Date:  2016-05-13       Impact factor: 2.327

4.  Oxysterols provide innate immunity to bacterial infection by mobilizing cell surface accessible cholesterol.

Authors:  Michael E Abrams; Kristen A Johnson; Sofya S Perelman; Li-Shu Zhang; Shreya Endapally; Katrina B Mar; Bonne M Thompson; Jeffrey G McDonald; John W Schoggins; Arun Radhakrishnan; Neal M Alto
Journal:  Nat Microbiol       Date:  2020-04-13       Impact factor: 17.745

5.  Interferon-lambda (IFN-λ) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes.

Authors:  Harold Dickensheets; Faruk Sheikh; Ogyi Park; Bin Gao; Raymond P Donnelly
Journal:  J Leukoc Biol       Date:  2012-12-20       Impact factor: 4.962

6.  Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus.

Authors:  Nikolaus Jilg; Wenyu Lin; Jian Hong; Esperance A Schaefer; David Wolski; James Meixong; Kaku Goto; Cynthia Brisac; Pattranuch Chusri; Dahlene N Fusco; Stephane Chevaliez; Jay Luther; Kattareeya Kumthip; Thomas J Urban; Lee F Peng; Georg M Lauer; Raymond T Chung
Journal:  Hepatology       Date:  2014-02-14       Impact factor: 17.425

7.  A genetic screen identifies interferon-α effector genes required to suppress hepatitis C virus replication.

Authors:  Dahlene N Fusco; Cynthia Brisac; Sinu P John; Yi-Wen Huang; Christopher R Chin; Tiao Xie; Hong Zhao; Nikolaus Jilg; Leiliang Zhang; Stephane Chevaliez; Daniel Wambua; Wenyu Lin; Lee Peng; Raymond T Chung; Abraham L Brass
Journal:  Gastroenterology       Date:  2013-02-24       Impact factor: 22.682

Review 8.  Hepatitis B Virus-Hepatocyte Interactions and Innate Immune Responses: Experimental Models and Molecular Mechanisms.

Authors:  Emmanuel Thomas; Thomas F Baumert
Journal:  Semin Liver Dis       Date:  2019-07-02       Impact factor: 6.512

9.  HELZ2 Is an IFN Effector Mediating Suppression of Dengue Virus.

Authors:  Dahlene N Fusco; Henry Pratt; Stephen Kandilas; Scarlett Se Yun Cheon; Wenyu Lin; D Alex Cronkite; Megha Basavappa; Kate L Jeffrey; Anthony Anselmo; Ruslan Sadreyev; Clarence Yapp; Xu Shi; John F O'Sullivan; Robert E Gerszten; Takuya Tomaru; Satoshi Yoshino; Tetsurou Satoh; Raymond T Chung
Journal:  Front Microbiol       Date:  2017-02-20       Impact factor: 5.640

10.  Restriction factor screening identifies RABGAP1L-mediated disruption of endocytosis as a host antiviral defense.

Authors:  Sonja Fernbach; Eva E Spieler; Idoia Busnadiego; Umut Karakus; Anouk Lkharrazi; Silke Stertz; Benjamin G Hale
Journal:  Cell Rep       Date:  2022-03-22       Impact factor: 9.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.